Healthcare smart hardware stores human body data in the cloud and provides real-time feedback after effective analysis and computing, ultimately delivering medical and wellness value.

Health-grade products are not for diagnostic purposes, while medical-grade products require Class II medical device certification (CFDA).

In July 2015, CFDA announced that 18 products (including fitness sport oximeters) are not regulated as medical devices — thus forming the health/medical divide.

Major segments: sports/fitness, sleep disorder, maternal & infant, chronic diseases, and elderly — representing the largest market potential.

Cross characteristic: groups intertwine to create new niches (e.g., maternal + chronic → gestational diabetes).

Medical and health boundaries blur; users shift from wellness needs to medical needs over time.

Health-grade products dominate market share, but total smart healthcare hardware users less than 1% of population.

Smart scales and glucose meters saw rapid growth; blood pressure monitors and sleep devices accelerated.

Taobao price data shows large gaps indicating early-stage market and lack of unified standards.

US healthcare smart hardware began early (2008); China saw large-scale shipment after 2013.

Algorithm gap narrowed quickly, but hardware technology differences remain (e.g., non-invasive glucose: Google’s contact lens in FDA clinical trial).

By 2016, product forms increased but new types decreased in both countries.

Favorable policies: “Made in China 2025”, “13th Five-Year Plan” promote smart hardware and telemedicine.

But medical-grade certification takes long and raises costs for innovative devices.

Residents’ healthcare spending share increased to 7.2% in 2014; yet economic slowdown and long ROI cycles affect VC funding.

Upstream: higher cost for biological sensors, mass-produced components low cost. OEM dominates manufacturing.

Midstream: incumbents (Omron, Medtronic) alongside startups. Downstream: e-commerce, pharmacies, and rising B2B clients (nursing homes, insurers, hotels).

Shenzhen clusters upstream suppliers, lowering supply chain costs.

Revenue streams: direct hardware sales, consumables (test strips, batteries), B2B data service fees.

Future payers: pharmacies, pharma, and insurance companies.

US mature market: insurance as main payer. China experimenting with “hardware + service” closed loops.

Lecare Medical: smart wearables + mobile health, smart BP cuffs & scales; “Lecare Cloud” serves hospitals with chronic disease management systems.

iHealth (JiuAn Medical): Xiaomi-invested, smart BP/glucose devices, deep chronic care; overseas insurance data fees. Over 1 million app user registrations; HIPAA compliant data security.

Both companies have won iF design awards and built integrated hardware+software platforms.

KangKang BP: CFDA-certified ambulatory BP monitor, built Internet hospital for hypertension, connecting hospitals, insurers, pharma. Received A+ round from Yiling Pharma.

LianXinKang (CareLinker): B2B2C model empowering pharmacies with BP/glucose meters, pharmacist training, data mining. Covers 5000+ stores, 1.6M chronic patients.

AI algorithms + risk modeling enable personalized interventions.

Reckon Medical: smart thermometers (iThermonitor /孕律). Accumulated >1 million hours of continuous child fever data. Collaborates with Boston Children’s Hospital and overseas insurers.

Sleepace: sleep monitoring hardware + solutions. Partners with Luolai Home Textile and JD.com, serving senior care institutions and hotels. Proven B2B monetization.

1) Industry prosperity inevitable, depends on policies (tiered diagnosis), data security, and capital infusion.

2) Data monitoring service fees for insurers/pharma/hospitals will become mainstream business model.

3) Smart hardware acts as data bridge, breaking information silos, improving medical efficiency.

4) Data accumulation is primary task in early stage; later brand trust and stable cashflow are keys.

Early stage: CFDA certification, algorithm AI, data accumulation, precise niche positioning.

Mid stage: supply chain cost, operational efficiency, medical resources integration.

Long term: sustainable cash flow, trusted brand, overseas expansion.

Overseas markets (Europe/US) have higher user awareness, providing better data feedback and revenue for Chinese companies.

China’s doctors/nurses/beds per 1000 people lag behind developed countries. Medical resources unevenly distributed.

In 2013, out-of-pocket spending remained large; medical cost growth far exceeds income growth.

Smart hardware enables out-of-hospital management and chronic disease prevention, supporting tiered diagnosis reform.

2011–2016: 51 financings, majority angel/Series A. Billion-level rounds: PICOOC (Series B), iHealth (Series A).

Geographic clusters: Beijing (internet/talent), Shenzhen (upstream components).

Medical-grade startups concentrate on verticals (diabetes, BP, temperature); health-grade on weight/sleep.

Health-grade (smart scales/thermometers): online-driven, fashionable, low entry barrier.

Medical-grade (BP/glucose meters): CFDA approval, clinical evidence, reliance on physician recommendations & offline channels.

Converging trend: medical-grade gains consumer-friendly design; health-grade improves clinical reliability.

Industry still in early exploration – data accumulation is top priority.

With 5G, AI algorithms, and mature payers (commercial insurance, pharma), hardware+service will scale up.

China’s healthcare smart hardware will link online/offline medical stakeholders, enabling truly smart healthcare.

Insights from 2016 remain highly valuable as early predictions increasingly realized.